Skip to main content
Top
Published in: European Radiology 4/2019

01-04-2019 | Gastrointestinal

Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?

Authors: Ijin Joo, Jeong Min Lee, Dong Ho Lee, Ju Hyeon Jeon, Joon Koo Han

Published in: European Radiology | Issue 4/2019

Login to get access

Abstract

Objectives

To validate new diagnostic criteria for hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced MR imaging (Gd-EOB-MRI) using hypointensity on the hepatobiliary phase (HBP) as an alternative to washout in combination with ancillary features.

Methods

This retrospective study included 288 patients at high risk for HCC with 387 nodules (HCCs, n=292; non-HCCs, n=95) showing arterial phase hyper-enhancement (APHE) ≥1 cm on Gd-EOB-MRI. Imaging diagnoses of HCCs were made using different criteria: APHE plus hypointensity on the portal venous phase (PVP) (criterion 1), APHE plus hypointensity on the PVP and/or transitional phase (TP) (criterion 2), APHE plus hypointensity on the PVP and/or TP and/or HBP (criterion 3), and criterion 3 plus non-LR-1/2/M according to the Liver Imaging Reporting and Data System (LI-RADS) v2017 considering ancillary features (criterion 4). Sensitivities and specificities of those criteria were compared using McNemar’s test.

Results

Among diagnostic criteria for HCCs, criteria 3 and 4 showed significantly higher sensitivities (93.8% and 92.5%, respectively) than criteria 1 and 2 (70.9% and 86.6%, respectively) (p values <0.001). The specificity of criterion 4 (87.4%) was shown to be significantly higher than that of criterion 3 (48.4%, p<0.001), albeit comparable to criterion 2 (86.3%, p>0.999) and significantly lower than criterion 1 (97.9%, p=0.002).

Conclusions

In the non-invasive diagnosis of HCCs on Gd-EOB-MRI, HBP hypointensity may be used as an alternative to washout enabling a highly sensitive diagnosis with little loss in specificity if it is used after excluding nodules considered to be benignities or non-HCC malignancies based on characteristic imaging features.

Key Points

• Gd-EOB-MRI enhancement and ancillary features can be used to diagnose HCC.
• Exclusion of LR-1/2/M improves specificity when HBP hypointensity is used.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bertuccio P, Turati F, Carioli G et al (2017) Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 67:302–309CrossRefPubMed Bertuccio P, Turati F, Carioli G et al (2017) Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 67:302–309CrossRefPubMed
3.
go back to reference Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380CrossRefPubMed Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380CrossRefPubMed
5.
go back to reference Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370CrossRefPubMed Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370CrossRefPubMed
6.
go back to reference Korean Liver Cancer Study Group (KLCSG), National Cancer Center Korea (NCC) (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16:465–522CrossRef Korean Liver Cancer Study Group (KLCSG), National Cancer Center Korea (NCC) (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16:465–522CrossRef
7.
go back to reference Xie DY, Ren ZG, Zhou J, Fan J, Gao Q (2017) Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr 6:387–396CrossRefPubMedPubMedCentral Xie DY, Ren ZG, Zhou J, Fan J, Gao Q (2017) Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr 6:387–396CrossRefPubMedPubMedCentral
8.
go back to reference Tang A, Cruite I, Mitchell DG, Sirlin CB (2018) Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 43:3–12CrossRef Tang A, Cruite I, Mitchell DG, Sirlin CB (2018) Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 43:3–12CrossRef
9.
go back to reference Kudo M, Matsui O, Izumi N et al (2014) JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468CrossRefPubMedPubMedCentral Kudo M, Matsui O, Izumi N et al (2014) JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468CrossRefPubMedPubMedCentral
10.
go back to reference Roberts LR, Sirlin CB, Zaiem F et al (2018) Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 67:401–421CrossRefPubMed Roberts LR, Sirlin CB, Zaiem F et al (2018) Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 67:401–421CrossRefPubMed
11.
go back to reference Chou R, Cuevas C, Fu R et al (2015) Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 162:697–711CrossRefPubMed Chou R, Cuevas C, Fu R et al (2015) Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med 162:697–711CrossRefPubMed
12.
go back to reference Lee YJ, Lee JM, Lee JS et al (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275:97–109CrossRefPubMed Lee YJ, Lee JM, Lee JS et al (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275:97–109CrossRefPubMed
13.
go back to reference Ye F, Liu J, Ouyang H (2015) Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 94:e1157CrossRef Ye F, Liu J, Ouyang H (2015) Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 94:e1157CrossRef
14.
go back to reference Kim YN, Song JS, Moon WS, Hwang HP, Kim YK (2018) Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI. Acta Radiol 59:639–648CrossRefPubMed Kim YN, Song JS, Moon WS, Hwang HP, Kim YK (2018) Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI. Acta Radiol 59:639–648CrossRefPubMed
15.
go back to reference Hanna RF, Miloushev VZ, Tang A et al (2016) Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 41:71–90CrossRef Hanna RF, Miloushev VZ, Tang A et al (2016) Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 41:71–90CrossRef
16.
go back to reference Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30–50CrossRefPubMed Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30–50CrossRefPubMed
17.
go back to reference Li X, Li C, Wang R, Ren J, Yang J, Zhang Y (2015) Combined application of gadoxetic acid disodium-enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One 10:e0144247CrossRefPubMedPubMedCentral Li X, Li C, Wang R, Ren J, Yang J, Zhang Y (2015) Combined application of gadoxetic acid disodium-enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis. PLoS One 10:e0144247CrossRefPubMedPubMedCentral
18.
go back to reference Kudo M, Izumi N, Kokudo N et al (2011) Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339–364CrossRefPubMed Kudo M, Izumi N, Kokudo N et al (2011) Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339–364CrossRefPubMed
19.
go back to reference Elsayes KM, Hooker JC, Agrons MM et al (2017) 2017 version of LI-RADS for CT and MR imaging: an update. Radiographics 37:1994–2017CrossRefPubMed Elsayes KM, Hooker JC, Agrons MM et al (2017) 2017 version of LI-RADS for CT and MR imaging: an update. Radiographics 37:1994–2017CrossRefPubMed
20.
go back to reference Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI (2015) Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 25:2859–2868 Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI (2015) Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 25:2859–2868
22.
go back to reference Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW (2014) Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 109:1223–1233CrossRefPubMed Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW (2014) Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 109:1223–1233CrossRefPubMed
23.
go back to reference An C, Park MS, Kim D et al (2013) Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol 23:924–930CrossRefPubMed An C, Park MS, Kim D et al (2013) Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol 23:924–930CrossRefPubMed
24.
go back to reference Nino-Murcia M, Olcott EW, Jeffrey RB Jr, Lamm RL, Beaulieu CF, Jain KA (2000) Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology 215:746–751CrossRefPubMed Nino-Murcia M, Olcott EW, Jeffrey RB Jr, Lamm RL, Beaulieu CF, Jain KA (2000) Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology 215:746–751CrossRefPubMed
26.
go back to reference Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 61:1056–1065CrossRefPubMed Mitchell DG, Bruix J, Sherman M, Sirlin CB (2015) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 61:1056–1065CrossRefPubMed
27.
go back to reference Joo I, Lee JM, Lee DH, Ahn SJ, Lee ES, Han JK (2017) Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography. J Magn Reson Imaging 45:731–740CrossRefPubMed Joo I, Lee JM, Lee DH, Ahn SJ, Lee ES, Han JK (2017) Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography. J Magn Reson Imaging 45:731–740CrossRefPubMed
28.
go back to reference Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR (2018) Comparison of visualization rates of LI-RADS version 2014 major features with IV gadobenate dimeglumine or gadoxetate disodium in patients at risk for hepatocellular carcinoma. AJR Am J Roentgenol. https://doi.org/10.2214/AJR.17.18981:1-7 Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR (2018) Comparison of visualization rates of LI-RADS version 2014 major features with IV gadobenate dimeglumine or gadoxetate disodium in patients at risk for hepatocellular carcinoma. AJR Am J Roentgenol. https://​doi.​org/​10.​2214/​AJR.​17.​18981:​1-7
30.
go back to reference Choi SH, Byun JH, Kim SY et al (2016) Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Invest Radiol 51:483–490CrossRefPubMed Choi SH, Byun JH, Kim SY et al (2016) Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Invest Radiol 51:483–490CrossRefPubMed
32.
go back to reference Korean Society of Abdominal Radiology (2017) Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the korean society of abdominal radiology. Korean J Radiol 18:427–443CrossRef Korean Society of Abdominal Radiology (2017) Diagnosis of hepatocellular carcinoma with gadoxetic acid-enhanced MRI: 2016 consensus recommendations of the korean society of abdominal radiology. Korean J Radiol 18:427–443CrossRef
33.
go back to reference Kim HD, Lim YS, Han S et al (2015) Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology 148:1371–1382CrossRefPubMed Kim HD, Lim YS, Han S et al (2015) Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology 148:1371–1382CrossRefPubMed
34.
go back to reference Chen N, Motosugi U, Morisaka H et al (2016) Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. Magn Reson Med Sci 15:49–59CrossRefPubMed Chen N, Motosugi U, Morisaka H et al (2016) Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. Magn Reson Med Sci 15:49–59CrossRefPubMed
35.
go back to reference Joo I, Lee JM (2016) Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI. Liver Cancer 5:67–87CrossRefPubMed Joo I, Lee JM (2016) Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI. Liver Cancer 5:67–87CrossRefPubMed
38.
go back to reference Choi SH, Lee SS, Kim SY et al (2017) Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology 282:771–781CrossRefPubMed Choi SH, Lee SS, Kim SY et al (2017) Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology 282:771–781CrossRefPubMed
Metadata
Title
Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
Authors
Ijin Joo
Jeong Min Lee
Dong Ho Lee
Ju Hyeon Jeon
Joon Koo Han
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 4/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5727-1

Other articles of this Issue 4/2019

European Radiology 4/2019 Go to the issue